CLINICAL_TRIALS
trial_result
· 2025-09-16
Clinical Trial Update: PRO 140 in Treatment-Experienced HIV-1 Subjects [Phase 2, Phase 3]
Summary
CytoDyn's PRO 140 (leronlimab) in treatment-experienced HIV-1 infection completed Phase 2/3 trials and posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: CytoDyn, Inc. | Conditions: HIV-1-infection | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2025-09-16